Raymond James Financial Services Advisors’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
FCM
SIMG
PM
Raymond James Financial Services Advisors's PCRX Position: Q3 2023 in Review
Raymond James Financial Services Advisors sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 5,713 shares — an estimated $229K sold.
Raymond James Financial Services Advisors first reported a position in PCRX in Q3 2018 and held it in 15 quarters. The position peaked at $372K in Q1 2021. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.
- Raymond James Financial Services Advisors reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
- Raymond James Financial Services Advisors sold 5,713 Pacira BioSciences shares in Q3 2023, an estimated $229K.
- Raymond James Financial Services Advisors first reported a position in Pacira BioSciences in Q3 2018 and held it in 15 quarters.
- Raymond James Financial Services Advisors's Pacira BioSciences position peaked at $372K in Q1 2021.
- 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.